Article

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas

2023-01-21

Abstract excerpt

Resistance to combination BRAF/MEK inhibitor (BRAFi/MEKi) therapy arises in nearly every patient with BRAF V600E/K melanoma, despite promising initial responses. Achieving cures in this expanding BRAFi/MEKi-resistant cohort represents one of the greatest challenges to the field; few experience additional durable benefit from immunotherapy and no alternative therapies exist. To better personalize therapy in cancer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4afcd4d6-57f9-5c98-b2a1-875532523bd6
DOI: 10.1101/2023.01.20.524923

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed MelanomasDOI 10.1101/2023.01.20.524923Read

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapySemantic proximity Read

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceSemantic proximity Read

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read

Multi-organ landscape of therapy-resistant melanomaSemantic proximity Read

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.Semantic proximity Read

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma.Semantic proximity Read

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Semantic proximity Read

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.Semantic proximity Read

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaSemantic proximity Read

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.Semantic proximity Read

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapySemantic proximity Read